scholarly journals Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation

2008 ◽  
Vol 123 (10) ◽  
pp. 2354-2361 ◽  
Author(s):  
Carla M.L. van Herpen ◽  
Robbert van der Voort ◽  
Jeroen A.W.M. van der Laak ◽  
Ina S. Klasen ◽  
Aniek O. de Graaf ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
B Cell ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cell Activation ◽  
Neck Squamous Cell Carcinoma ◽  
B Cell Activation

scholarly journals Expression and Prognostic Value of IFIT1 and IFITM3 in Head and Neck Squamous Cell Carcinoma

2020 ◽  
Vol 153 (5) ◽  
pp. 618-629
Author(s):  
Hao Li ◽  
Lei-Lei Yang ◽  
Cong-Cong Wu ◽  
Yao Xiao ◽  
Liang Mao ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
T Cell Activation ◽  
Squamous Cell ◽  
Cell Activation ◽  
Transmembrane Protein ◽  
Normal Mucosa ◽  
Neck Squamous Cell Carcinoma ◽  
Type I

Abstract Objectives Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) and interferon-induced transmembrane protein 3 (IFITM3) are commonly induced by type I interferon. The study aims to investigate the expression and clinical significance of IFIT1 and IFITM3 in head and neck squamous cell carcinoma (HNSCC). Methods Immunohistochemistry was applied on tissue microarray to reveal IFIT1 and IFITM3 expression in 275 HNSCC, 69 dysplasia, and 42 normal mucosa samples. The clinicopathologic features associated with IFIT1 and IFITM3 expression in HNSCC patients were analyzed. Results IFIT1 and IFITM3 were highly expressed in HNSCC tissues. High expression of IFIT1 and IFITM3 predicts a negative prognosis for patients (P < .01). IFIT1 and IFITM3 expression was associated with programmed cell death ligand 1, B7-H4, V-domain Ig suppressor of T-cell activation, indoleamine 2,3-dioxygenase, and macrophage marker immunoreactivity. Conclusions IFIT1 and IFITM3 were overexpressed in HNSCC and indicated poor prognoses for patients with HNSCC. IFIT1 and IFITM3 expression was correlated with several immune checkpoint molecules and tumor-associated macrophage markers.

Characterization of tumor-associated B cell subsets in head and neck squamous cell carcinoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e22108-e22108 ◽  
Author(s):  
Sacha Rothschild ◽  
Alex Lechner ◽  
Hans Anton Schloesser ◽  
Martin Thelen ◽  
Alexander Shimabukuro-Vornhagen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
B Cell ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
B Cell Subsets

scholarly journals Rituximab in Combination with Gemcitabine Plus Cisplatin in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I Trial

2021 ◽  
Author(s):  
Ching-Yun Hsieh ◽  
Ming-Yu Lien ◽  
Chen-Yuan Lin ◽  
Wen-Jyi Lo ◽  
Chung-Hung Hua ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
T Cells ◽  
Phase I ◽  
B Cell ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Cell Depletion ◽  
B Cell Depletion

Abstract BackgroundThe treatment of recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC) remains challenging. Preclinical studies revealed that B cell depletion could modulate the microenvironment and overcome chemoresistance. We conducted a phase I study to evaluate the feasibility and safety of B cell depletion using the anti-CD20 antibody rituximab to treat HNSCC.MethodsTen patients were enrolled into two protocols. The first four patients treated using protocol 1 received rituximab 1000 mg on days −14 and −7, followed by gemcitabine/cisplatin every 3 weeks, and rituximab was administered every 6 months thereafter. Because of disease hyperprogression, protocol 1 was amended to protocol 2, which consisted of the concomitant administration of rituximab 375 mg/m2 and gemcitabine/cisplatin every 3 weeks. Another six patients were enrolled and treated using protocol 2.ResultsThree patients treated using protocol 1 exhibited rapid disease progression, and the remaining patient could not undergo evaluation after rituximab treatment. Conversely, no unpredicted harm was observed in the six patients treated using protocol 2. Among these patients, one achieved complete response, and two had partial responses. The disease-free durations in these patients were 7.0, 6.2, and 7.1 months, respectively. Immune cell analysis revealed a higher ratio of cytotoxic T cells to regulatory T cells in responders than in non-responders.ConclusionsB cell depletion using rituximab alone in patients with HNSCC can cause hyperprogressive disease. Contrarily, the co-administration of rituximab and cisplatin/gemcitabine was feasible and safe.Trial registration:ClinicalTrials.gov Identifier: NCT04361409, 24/April/2020, retrospectively registered, https://clinicaltrials.gov/ct2/show/study/NCT04361409

Sign in / Sign up

Export Citation Format

Share Document